IP Library Granted Patent US 12,083,218
Granted Patent B2
US 12,083,218 · App. 17/447,453 · Granted Sep 10, 2024

Soft chewable dosage form

Inventors: Gregory E. Koll (Hillsborough, NJ); Gerard P. McNally (Derwyn, PA); Vipul Dave (Hillsborough, NJ)
Assignee: Johnson & Johnson Consumer Inc.
A61K9/0056A23L27/33A23L27/84A23L33/10A61K9/127A61K31/426
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,083,218
App. No.
17/447,453
Granted
Sep 10, 2024
Kind
B2
Abstract

The invention relates to a soft chewable dosage form comprising a first active pharmaceutical ingredient encapsulated in a lipid material that is embedded in the soft chewable dosage form and wherein the soft chewable dosage form comprises at least a second active pharmaceutical ingredient as well as a method of treating a subject suffering from a disease or disorder in the gastro intestinal tract using the soft chewable dosage form.

Claims (3)

1. A method for treating a subject suffering from a disease or disorder in the gastro intestinal tract comprising administering a soft chewable dosage form comprising a first active pharmaceutical ingredient encapsulated in a lipid material/matrix comprising a first lipid and a second lipid, wherein the second lipid is a plasticizer, wherein the lipid encapsulated active pharmaceutical ingredient is embedded in the soft chewable dosage form, and wherein the soft chewable dosage form comprises at least a second active pharmaceutical ingredient.

2. A method according to claim 1 , wherein the disease or disorder in the gastro intestinal tract is peptic ulcers, gastric ulcers, hyperacidity, gastroesophageal reflux disease (GERD), or gastritis.

3. A method according to claim 1 , wherein the disease or disorder in the gastro intestinal tract leads to heartburn, gas, indigestion, upper abdominal fullness, heartburn, nausea, belching, upper abdominal pain, or feeling full earlier than expected when eating.

Assignments (7)
CHANGE OF NAME Recorded Oct 28, 2024
From: JOHNSON & JOHNSON CONSUMER INC.
To: KENVUE BRANDS LLC
Reel/Frame 069267/0143 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2023
From: JOHNSON & JOHNSON CONSUMER INC.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 062438/0372 →
CERTIFICATE OF CONVERSION Recorded Jan 19, 2023
From: JOHNSON & JOHNSON CONSUMER INC.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 062438/0521 →
MERGER Recorded Jan 27, 2022
From: JOHNSON & JOHNSON CONSUMER INC.
To: CHENANGO ZERO LLC
Reel/Frame 059618/0521 →
MERGER Recorded Jan 27, 2022
From: CHENANGO ZERO LLC
To: CHENANGO TWO LLC
Reel/Frame 058888/0133 →
MERGER AND CHANGE OF NAME Recorded Jan 27, 2022
From: CHENANGO TWO LLC; CURRAHEE HOLDING COMPANY INC.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 058888/0210 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2021
From: DAVE, VIPUL; KOLL, GREGORY E.; MCNALLY, GERARD P.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 057457/0682 →
Continuity (3)
Division 16654107 · Oct 16, 2019
Provisional Application 62747267 · Oct 18, 2018
Related Publication 20210401739A1 · Dec 30, 2021